Amylyx Pharmaceuticals Inc
AMLX.O- Latest Trade
- trading higher25.27USD
- Change
- 0.21
- % Change
0.84%Positive
- As of Aug 15 2022. Values delayed up to 15 minutes
- Day Range
- 24.58 - 26.06
- 52-Week Range
- 6.51 - 33.41
- Previous Close
- 25.06
- Open
- 25.45
- Volume
- 371,914.00
- 3 Month Average Trading Volume
- 19.94
- Shares Out (Mil)
- 58.53
- Market Cap
- 1,466.84
- Forward P/E
- -7.64
- Dividend Yield
- -99,999.99
Key Statistics
1.8 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 5,146.82
- Price To Book (Quarterly)
- 6.02
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -99,999.99
- Return On Equity (TTM)
- -99,999.99
2021 (millions USD)
About Amylyx Pharmaceuticals Inc (AMLX.O)
Company Information
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The Company is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.
Address
43 THORNDIKE STREETCAMBRIDGE, MA
02141
United States
Industry
Business Services
Executive Leadership
- George Mclean Milne
- Independent Non-Executive Chairman of the Board
- Joshua B. Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Co-Chief Executive Officer, Director
- James M. Frates
- Chief Financial Officer
- Gina M. Mazzariello
- Chief Legal Officer and General Counsel
- Margaret Olinger
- Chief Commercial Officer
- Patrick D. Yeramian
- Chief Medical Officer
- Isaac Cheng
- Independent Director
- Paul Fonteyne
- Independent Director
- Daphne E. Quimi
- Independent Director
Latest News
- BusinessAmylyx's ALS drug would not be cost effective if priced around $170,000- ICER
Amylyx Pharmaceuticals Inc's experimental drug for neurodegenerative disease amyotrophic lateral sclerosis (ALS) would not be cost effective if priced around $170,000, an independent U.S. pricing watchdog said on Tuesday.
- BusinessAmylyx gets first approval for ALS drug from Canada
Canada has approved Amylyx Pharmaceuticals' treatment for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, the drugmaker said on Monday, the first such approval for the oral drug.
- BusinessU.S. FDA panel votes against Amylyx's ALS drug over trial data concerns
A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday voted against approving Amylyx Pharmaceuticals Inc's drug for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
- MarketsDiscovery, T-Mobile, NYT, Texas Instruments
Wall Street's main indexes were mixed in choppy trading on Friday after data pointed to weaker-than-expected job growth last month, further fueling bets of an aggressive monetary policy tightening by the Federal Reserve.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,777.10 | 0.24%Negative |
| Copper | 676.30 | 0.70%Negative |
| Brent Crude Oil | 94.28 | 0.86%Negative |
| CBOT Soybeans | 1,484.00 | 0.67%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,297.14 | 0.40%Positive |
| Euro STOXX 50 | 3,789.62 | 0.34%Positive |
| FTSE 100 | 7,509.15 | 0.11%Positive |
| Nikkei 225 | 28,869.42 | 0.01%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes